Page 821 - Read Online

Alqahtani et al. Hepatoma Res 2020;6:70 I http://dx.doi.org/10.20517/2394-5079.2020.65 Page 15 of 15

the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies. J Clin Oncol 2019;37:4079.
85. Gou M, Zhang Y, Si H, Dai G. Efficacy and safety of nivolumab for metastatic biliary tract cancer. Onco Targets Ther 2019;12:861-7.
86. Kim RD, Kim DW, Alese OB, Li D, Shah N, et al. A phase II study of nivolumab in patients with advanced refractory biliary tract cancers
(BTC). J Clin Oncol 2019;37:4097.
87. Ueno M, Ikeda M, Morizane C, Kobayashi S, Ohno I, et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in
Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet
Gastroenterol Hepatol 2019;4:611-21.
88. Ioka T, Ueno M, Oh DY, Fujiwara Y, Chen JS, et al. Evaluation of safety and tolerability of durvalumab (D) with or without
tremelimumab (T) in patients (pts) with biliary tract cancer (BTC). J Clin Oncol 2019;37:387.